Amphastar Pharmaceuticals Inc (AMPH)

$39.62

-0.53

(-1.32%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Amphastar Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 180.55M → 178.10M (in $), with an average decrease of 1.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 49.22M → 36.16M (in $), with an average decrease of 26.5% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 31.0% return, outperforming this stock by 37.0%

Performance

  • $38.95
    $40.18
    $39.62
    downward going graph

    1.69%

    Downside

    Day's Volatility :3.05%

    Upside

    1.38%

    downward going graph
  • $35.62
    $67.66
    $39.62
    downward going graph

    10.1%

    Downside

    52 Weeks Volatility :47.35%

    Upside

    41.44%

    downward going graph

Returns

PeriodAmphastar Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-28.61%
-1.1%
0.0%
6 Months
-14.74%
6.7%
0.0%
1 Year
-5.58%
3.2%
-0.7%
3 Years
128.36%
15.2%
-21.6%

Highlights

Market Capitalization
1.9B
Book Value
$13.3
Earnings Per Share (EPS)
2.6
PE Ratio
15.47
PEG Ratio
2.77
Wall Street Target Price
68.5
Profit Margin
21.35%
Operating Margin TTM
30.31%
Return On Assets TTM
11.07%
Return On Equity TTM
23.55%
Revenue TTM
644.4M
Revenue Per Share TTM
13.35
Quarterly Revenue Growth YOY
31.900000000000002%
Gross Profit TTM
248.9M
EBITDA
237.7M
Diluted Eps TTM
2.6
Quarterly Earnings Growth YOY
0.06
EPS Estimate Current Year
3.74
EPS Estimate Next Year
4.32
EPS Estimate Current Quarter
0.91
EPS Estimate Next Quarter
0.75

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Amphastar Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 72.89%

Current $39.62
Target $68.50

Company Financials

FY18Y/Y Change
Revenue
294.7M
↑ 22.69%
Net Income
-5.7M
↓ 227.28%
Net Profit Margin
-1.95%
↓ 3.83%
FY19Y/Y Change
Revenue
322.4M
↑ 9.4%
Net Income
48.9M
↓ 952.89%
Net Profit Margin
15.18%
↑ 17.13%
FY20Y/Y Change
Revenue
349.8M
↑ 8.53%
Net Income
1.1M
↓ 97.76%
Net Profit Margin
0.31%
↓ 14.87%
FY21Y/Y Change
Revenue
437.8M
↑ 25.13%
Net Income
62.1M
↑ 5562.35%
Net Profit Margin
14.19%
↑ 13.88%
FY22Y/Y Change
Revenue
499.0M
↑ 13.98%
Net Income
91.4M
↑ 47.12%
Net Profit Margin
18.31%
↑ 4.12%
FY23Y/Y Change
Revenue
644.4M
↑ 29.14%
Net Income
137.5M
↑ 50.51%
Net Profit Margin
21.34%
↑ 3.03%
Q3 FY22Q/Q Change
Revenue
120.1M
↓ 2.7%
Net Income
15.9M
↓ 8.49%
Net Profit Margin
13.21%
↓ 0.84%
Q4 FY22Q/Q Change
Revenue
135.0M
↑ 12.4%
Net Income
33.9M
↑ 113.64%
Net Profit Margin
25.12%
↑ 11.91%
Q1 FY23Q/Q Change
Revenue
140.0M
↑ 3.7%
Net Income
26.0M
↓ 23.24%
Net Profit Margin
18.59%
↓ 6.53%
Q2 FY23Q/Q Change
Revenue
145.7M
↑ 4.06%
Net Income
26.1M
↑ 0.35%
Net Profit Margin
17.93%
↓ 0.66%
Q3 FY23Q/Q Change
Revenue
180.6M
↑ 23.91%
Net Income
49.2M
↑ 88.42%
Net Profit Margin
27.26%
↑ 9.33%
Q4 FY23Q/Q Change
Revenue
178.1M
↓ 1.36%
Net Income
36.2M
↓ 26.52%
Net Profit Margin
20.31%
↓ 6.95%
FY18Y/Y Change
Total Assets
513.6M
↑ 12.95%
Total Liabilities
149.2M
↑ 27.16%
FY19Y/Y Change
Total Assets
587.0M
↑ 14.29%
Total Liabilities
159.4M
↑ 6.86%
FY20Y/Y Change
Total Assets
631.2M
↑ 7.54%
Total Liabilities
182.5M
↑ 14.47%
FY21Y/Y Change
Total Assets
671.5M
↑ 6.38%
Total Liabilities
226.0M
↑ 23.83%
FY22Y/Y Change
Total Assets
742.0M
↑ 10.49%
Total Liabilities
213.3M
↓ 5.61%
FY23Y/Y Change
Total Assets
1.5B
↑ 103.9%
Total Liabilities
873.5M
↑ 309.46%
Q3 FY22Q/Q Change
Total Assets
726.7M
↑ 0.41%
Total Liabilities
221.5M
↓ 1.28%
Q4 FY22Q/Q Change
Total Assets
742.0M
↑ 2.1%
Total Liabilities
213.3M
↓ 3.7%
Q1 FY23Q/Q Change
Total Assets
773.7M
↑ 4.27%
Total Liabilities
225.1M
↑ 5.51%
Q2 FY23Q/Q Change
Total Assets
1.4B
↑ 78.15%
Total Liabilities
789.0M
↑ 250.56%
Q3 FY23Q/Q Change
Total Assets
1.5B
↑ 12.07%
Total Liabilities
949.5M
↑ 20.34%
Q4 FY23Q/Q Change
Total Assets
1.5B
↓ 2.05%
Total Liabilities
873.5M
↓ 8.0%
FY18Y/Y Change
Operating Cash Flow
38.2M
↓ 2.6%
Investing Cash Flow
-42.2M
↑ 8.84%
Financing Cash Flow
25.0M
↓ 424.02%
FY19Y/Y Change
Operating Cash Flow
41.8M
↑ 9.35%
Investing Cash Flow
-50.5M
↑ 19.78%
Financing Cash Flow
-3.8M
↓ 115.13%
FY20Y/Y Change
Operating Cash Flow
57.3M
↑ 37.12%
Investing Cash Flow
-36.4M
↓ 27.93%
Financing Cash Flow
-2.2M
↓ 40.63%
FY21Y/Y Change
Operating Cash Flow
98.0M
↑ 71.12%
Investing Cash Flow
-28.7M
↓ 21.26%
Financing Cash Flow
-37.0M
↑ 1548.17%
FY22Y/Y Change
Operating Cash Flow
89.2M
↓ 8.99%
Investing Cash Flow
-32.8M
↑ 14.32%
Financing Cash Flow
-26.4M
↓ 28.58%
Q3 FY22Q/Q Change
Operating Cash Flow
20.4M
↑ 623.8%
Investing Cash Flow
-15.3M
↑ 86.53%
Financing Cash Flow
-13.9M
↑ 1301.51%
Q4 FY22Q/Q Change
Operating Cash Flow
15.2M
↓ 25.27%
Investing Cash Flow
-229.0K
↓ 98.5%
Financing Cash Flow
-16.2M
↑ 16.01%
Q1 FY23Q/Q Change
Operating Cash Flow
40.4M
↑ 165.22%
Investing Cash Flow
-6.3M
↑ 2665.5%
Financing Cash Flow
-13.5M
↓ 16.17%
Q2 FY23Q/Q Change
Operating Cash Flow
54.9M
↑ 36.01%
Investing Cash Flow
-508.6M
↑ 7930.66%
Financing Cash Flow
428.1M
↓ 3259.96%

Technicals Summary

Sell

Neutral

Buy

Amphastar Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc
-7.97%
-14.74%
-5.58%
128.36%
90.48%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-3.19%
18.54%
29.33%
41.75%
58.78%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-3.61%
-2.91%
-7.72%
8.1%
8.1%
Zoetis Inc.
Zoetis Inc.
-13.09%
-14.39%
-14.11%
-9.35%
48.11%
Viatris Inc.
Viatris Inc.
-5.11%
19.64%
14.33%
-14.68%
-30.66%
Catalent, Inc.
Catalent, Inc.
0.14%
21.02%
23.93%
-49.27%
26.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc
15.47
15.47
2.77
3.74
0.24
0.11
NA
13.3
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
55.91
55.91
0.45
4.77
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.17
28.17
1.71
0.46
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
32.19
32.19
2.81
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
232.9
232.9
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.08
0.45
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc
Buy
$1.9B
90.48%
15.47
21.35%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.7B
58.78%
55.91
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$37.3B
8.1%
28.17
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$74.7B
48.11%
32.19
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.8B
-30.66%
232.9
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.3B
26.77%
211.02
-31.77%

Institutional Holdings

  • BlackRock Inc

    12.55%
  • Federated Hermes Inc

    6.80%
  • Vanguard Group Inc

    5.85%
  • Neuberger Berman Group LLC

    3.52%
  • State Street Corporation

    3.06%
  • Dimensional Fund Advisors, Inc.

    2.78%

Company Information

amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int

Organization
Amphastar Pharmaceuticals Inc
Employees
1761
CEO
Dr. Ziping Luo Ph.D.
Industry
Health Technology

FAQs